med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile. The companies believe that GenomOncology's proprietary technology platform, the GO Clinical WorkbenchTM, and support services will complement med fusion's expanded solid tumor disease-specific panels and deliver a comprehensive laboratory report detailing relevant drug and clinical trial options.
med fusion's solid tumor menu expansion is anticipated early Q3, 2014 with the launch of disease specific panels including NSCLC (Non Small Cell Lung Cancer) and CRC (Colorectal Cancer). The expanded oncology menu is powered in part by Next Generation Sequencing (NGS technology that med fusion validated in the summer of 2014 in its CLIA and CAP accredited laboratory.)
GenomOncology's GO Clinical Workbench streamlines the use of Next Generation Sequencing (NGS) data in conjunction with other analytic modalities, simplifies the creation of a summary report, and provides a fully traceable workflow and rules-based decision support for the clinical interpretation of genomic data. The platform is configured to each clinical laboratory's specific needs with systems integration (LIMS, EMR, etc.), setting of quality control and annotation parameters, and design of the resultant clinical report.
"Cancer is a complex disease of the genome where each tumor has its own set of genetic alterations," commented Dr. Tom Lohmann, CMO, med fusion. "Increased understanding of the underlying genetic changes that may be driving tumor growth or metastasis can enable precise treatment strategies tailored to the genetic profile of each patient's cancer."
"Genomics-based precision medicine requires the clinical interpretation of genomic data - streamlined use of Next Generation Sequencing information in conjunction with other analytic modalities – as well as rules-based decision support," continued Manuel Glynias, President and CEO of GenomOncology. "The availability of an expert knowledge base like My Cancer Genome, exclusively integrated with the GO Clinical Workbench provides a clinical report that educates physicians and gives them confidence as they make treatment decisions for patients."
"Our laboratory employs a multi-technology approach to solid tumor profiling in order to present a more complete set of treatment options as defined by the laboratory results," continued Jon Hart, CEO, med fusion. "Our partnership with GenomOncology combines these laboratory results with the peer-reviewed clinical expertise and clinical trial matching methodology of My Cancer Genome."
Cognitive behavioral therapy shows promise for prolonged grief disorder